ERBB2 and colorectal carcinoma: Patients with high-grade, advanced-stage CRC, accompanied by lymph node metastasis and lymphovascular invasion, and who demonstrate HER2/neu overexpression are potential candidates for monoclonal antibody-based targeted therapy.